F2G's Unattributed VC - III Round

F2G raised a round of funding on June 20, 2016.

F2G is advancing F901318, a novel clinical stage candidate for the treatment of invasive aspergillosis – a serious pulmonary infection caused by Aspergillus, a common fungus that affects people with…

Articles about F2G's Unattributed VC - III Round: